Friday 3rd May 2024 |
Text too small? |
AFT Pharmaceuticals to announce full year results on Thursday May 23 2024
AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announced today that it intends to release its full year FY2024, ended March 31 2024, results on Thursday May 23 2024. The release will be issued at around 09:00 am (NZT) on the NZX and ASX.
Following the release, management will present via webinar at 10:30 am (NZT). Presentation material will be available on the company’s website AFT, the NZX website NZX and the ASX website ASX.
To participate in the upcoming earnings webinar, please pre-register with the provided link, below. Webinar details will be provided upon completion of your registration.
Registration Link: AFT results presentation FY2024
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.
For more information:
Investors Media
Malcolm Tubby Richard Inder
CFO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: malcolm@aftpharm.com Email: richard@theproject.co.nz
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com
AFT Pharmaceuticals to announce full year results on Thursday May 23 2024
No comments yet
Mercury appoints new Chief Sustainability Officer
April 24th Morning Report
VCT - Operational performance for 9 months ended 31 March 2025
April 23rd Morning Report
TWR - Capital Return - ATO Class Ruling Obtained
THL - FY25 Trading Update
April 17th Morning Report
EBOS announces opening of Retail Offer
MCY - FY2025 EBITDAF guidance revised to $760m
April 16th Morning Report